Date: 29-Aug-2019

U.S. judge rules for Sanofi in Amgen patent fight

U.S. judge on Wednesday set aside a jury verdict that Amgen Inc patents on its cholesterol medication Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc and Sanofi SA, which make a rival drug. The ruling from U.S. District Judge Richard Andrews in Wilmington, Delaware was the latest reversal of fortune in a long-running lawsuit in which Amgen is seeking to stop Sanofi and Regeneron from selling their drug Praluent. The drug competes with Repatha and is intended to lower so-called bad LDL cholesterol by blocking a protein known as PCSK9